Scientific Evaluation of Cardio Protective Activity of Eachuramooli (Aristolochia indica Linn) in Animal Models

Abstract

The present research investigation was systematically carried out to predict the safety and efficacy of the novel siddha formulation Eachuramooli Chooranamin the management of Myocardial infarction and atherosclerosis by suitable in-vitro and in-vivo experimental animal models. Physiochemical evaluation of EC proves the standard and genunity of the prepared formulation. The results obtained from the phytochemical analysis of EC reveals the presence of phytocomponents such as alkaloids, tannins, carbohydrates, sterols and proteins. HPTLC reveals presence of 09 prominent peaks. Heavy metal analysis reveals the absence of arsenic, mercury and cadmium further results reveals the presence of lead with in the permissible limit. In-vitro DPPH, NO and H2O2 analysis exhibits that EC has potential anti-oxidant property against the free radicals in the tested medium. In vitro thrombolytic activity of various concentration of EC were carried out which indicated up to 48.84% of clot lysis activity of the drug EC when compared to 85.54% in case of Streptokinase. The in vitro anti platelet aggregation characteristics of EC at various concentration (100, 200, 300, 400 and 500 and#956;g/ml) when compared to the standard drug Aspirin showed 91 mean % activity were 27.93, 45.33, 69.63, 74.67 and 80.67 respectively. The acute toxicity study results have revealed that the drug EC was safe at the maximum dose level of 2000mg/kg which was higher than the normal therapeutic dose of the drug. Treatment with EC at all three dose level have shown dose dependent decrease in inflammatory cytokine level IL-6 in plasma of rats. In conclusion the siddha formulation Eachuramooli Chooranam belongs to Siddha system of traditional medicines showed potential anti-oxidant, anti-platelet, anti-thrombotic and cardio protective activity in the experimental animals. Hence this study provides evidence based results on the use of Eachuramooli Chooranam for clinical management of cardiovascular disorder in humans with proper clinical justification in near future.